# Respiratory Syncytial Virus fusion protein (BDI064): sc-57998



The Power to Question

### **BACKGROUND**

Respiratory Syncytial Virus (RSV) is a major cause of respiratory illness in children who have not received the vaccine or treatment. Respiratory Syncytial Virus is a negative sense, enveloped, RNA virus. The virion has an average diameter between 120 and 300 nm. The fusion protein of the RSS 2 strain (subtype A) directs fusion of viral and cellular membranes, results in viral penetration, and can form syncytia or multi-nucleated giant cells. The matrix protein plays a role in viral assembly and has been observed to traffic into and out of the nucleus at specific times during the respiratory infectious cycle. The matrix protein has also been shown to be able to inhibit transcription, which may be a key to respiratory pathogenesis.

## **REFERENCES**

- Belshe, R.B., Newman, F.K., Anderson, E.L., Wright, P.F., Karron, R.A., Tollefson, S., Henderson, F.W., Meissner, H.C., Madhi, S., Roberton, D., Marshall, H., Loh, R., Sly, P., Murphy, B., Tatem, J.M., Randolph, V., et al. 2004. Evaluation of combined live, attenuated Respiratory Syncytial Virus and parainfluenza 3 virus vaccines in infants and young children. J. Infect. Dis. 190: 2096-2103.
- Sastre, P., Melero, J.A., García-Barreno, B. and Palomo, C. 2004. Comparison of antibodies directed against human Respiratory Syncytial Virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities. Vaccine 23: 435-443.
- 3. Weir, E. and Fisman, D.N. 2004. Respiratory Syncytial Virus: pervasive yet evasive. CMAJ 170: 191.
- Brock, S.C., Heck, J.M., McGraw, P.A. and Crowe, J.E. 2005. The transmembrane domain of the Respiratory Syncytial Virus F protein is an orientation-independent apical plasma membrane sorting sequence. J. Virol. 79: 12528-12535.
- Playfor, S.D. and Khader, A. 2005. Arrhythmias associated with Respiratory Syncytial Virus infection. Paediatr. Anaesth. 15: 1016-1018.
- Becker, Y. 2006. Respiratory syncytial virus(RSV)-induced allergy may be controlled by IL-4 and CX3C fractalkine antagonists and CpG ODN as adjuvant: hypothesis and implications for treatment. Virus Genes 33: 253-264.
- Cilla, G., Sarasua, A., Montes, M., Arostegui, N., Vicente, D., Perez-Yarza, E. and Perez-Trallero, E. 2006. Risk factors for hospitalization due to Respiratory Syncytial Virus infection among infants in the Basque Country, Spain. Epidemiol. Infect. 134: 506-513.
- Ghildyal, R., Ho, A. and Jans, D.A. 2006. Central role of the Respiratory Syncytial Virus matrix protein in infection. FEMS Microbiol. Rev. 30: 692-705.
- Nunes, I.F. and Moura, F.E. 2006. Isolation of Respiratory Syncytial Virus from nasopharyngeal aspirates stored at 20° C from one to fifteen months after collection. Mem. Inst. Oswaldo Cruz 101: 451-453.

# **SOURCE**

Respiratory Syncytial Virus fusion protein (BDI064) is a mouse monoclonal antibody raised against Respiratory Syncytial Virus viral lysate (Long strain).

#### **PRODUCT**

Each vial contains 100  $\mu g \; lg G_1$  in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

## **APPLICATIONS**

Respiratory Syncytial Virus fusion protein (BDI064) is recommended for detection of fusion protein types A and B of Respiratory Syncytial Virus by immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

### **SELECT PRODUCT CITATIONS**

- Hu, X., Li, X., Hu, C., Qin, L., He, R., Luo, L., Tang, W. and Feng, J. 2017. Respiratory Syncytial Virus exacerbates OVA-mediated asthma in mice through C5a-C5aR regulating CD4+T cells immune responses. Sci. Rep. 7: 15207.
- Hu, X., Feng, J., Zhou, Q., Luo, L., Meng, T, Zhong, Y., Tang, W., Deng, S. and Li, X. 2019. Respiratory syncytial virus exacerbates kidney damages in IgA nephropathy mice via the C5a-C5aR1 axis orchestrating Th17 cell responses. Front. Cell. Infect. Microbiol. 9: 151.

### **STORAGE**

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

#### **PROTOCOLS**

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com